Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration

Inclusion Criteria:

• Received at least 2 and no more than 3 monthly Lucentis or Avastin injections
• Last Lucentis or Avastin was injected approximately 4 weeks prior to screening
• Visual acuity between 20/320 and 20/40

Exclusion Criteria:

• Active ocular infection
• Contraindication to pupil dilation in either eye
• Eye surgery including cataract surgery and/or laser of any type within 3 months